The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | The potential of fixed-duration BTKis and using MRD to guide treatment discontinuation in WM
Neil Berinstein, MD, Sunnybrook Odette Cancer Centre, Toronto, Canada, discusses the debate between fixed-duration and continuous BTK inhibitor (BTKi) treatment in Waldenström’s macroglobulinemia and other malignancies. He advocates for fixed-duration therapy due to the issue of cumulative toxicities associated with continuous administration of BTKis and suggests that measurable residual disease (MRD) could be used to guide treatment discontinuation. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: AstraZeneca; Advisory Board: AstraZeneca, Abbvie, BeiGene.
